DDInter624 DDInter111
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apremilast
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Hepatic enzyme increased {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apremilast
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Hepatic enzyme increased {u} (Side Effect) is caused by {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Fosphenytoin
Fosphenytoin {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Efavirenz {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Efavirenz {u} (Compound) causes {v} (Side Effect) Tremor
Tremor {u} (Side Effect) is caused by {v} (Compound) Fosphenytoin
Fosphenytoin {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Efavirenz {u} (Compound) causes {v} (Side Effect) Vertigo
Vertigo {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Efavirenz (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Efavirenz (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Fosphenytoin (Compound) and Fosphenytoin may lead to a major life threatening interaction when taken with Apremilast
Efavirenz (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Apremilast
Efavirenz (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Fosphenytoin (Compound) and Fosphenytoin may lead to a major life threatening interaction when taken with Apremilast
Efavirenz (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Apremilast